Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) had its target price decreased by stock analysts at HC Wainwright from $64.00 to $58.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright‘s target price would indicate a potential upside of 107.44% from the stock’s current price.
CLDX has been the subject of a number of other research reports. Stifel Nicolaus set a $68.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Thursday, October 15th. Leerink Partners lifted their target price on shares of Celldex Therapeutics from $70.00 to $88.00 and gave the company an “outperform” rating in a research note on Wednesday, September 23rd. Canaccord Genuity Group upped their price objective on shares of Celldex Therapeutics from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Finally, Barclays increased their price objective on Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $63.58.
Get Our Latest Research Report on Celldex Therapeutics
Celldex Therapeutics Stock Performance
Shares of CLDX opened at $27.96 on Friday. Celldex Therapeutics has a 12-month low of $22.33 and a 12-month high of $45.14. The business’s fifty day moving average price is $31.11 and its 200 day moving average price is $32.83.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.06. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.72 million. As a group, research analysts anticipate that Celldex Therapeutics will post -4.12 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of Celldex Therapeutics by 11.5% in the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock valued at $355,120,000 after purchasing an additional 983,195 shares during the last quarter. Commodore Capital LP grew its holdings in Celldex Therapeutics by 5.1% in the 1st quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company’s stock valued at $85,537,000 after buying an additional 131,616 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in Celldex Therapeutics by 116.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 2,564,984 shares of the biopharmaceutical company’s stock valued at $83,131,000 after buying an additional 1,382,373 shares during the last quarter. Eversept Partners LP increased its position in Celldex Therapeutics by 24.6% in the 1st quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock worth $56,716,000 after buying an additional 353,291 shares during the period. Finally, Fisher Asset Management LLC increased its position in Celldex Therapeutics by 26.5% in the 3rd quarter. Fisher Asset Management LLC now owns 1,246,855 shares of the biopharmaceutical company’s stock worth $40,411,000 after buying an additional 261,178 shares during the period.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.
Further Reading
- Five stocks we like better than Celldex Therapeutics
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
